英語 での Draft guidance の使用例とその 日本語 への翻訳
{-}
-
Colloquial
-
Ecclesiastic
-
Computer
-
Programming
Unicef publishes draft guidance on children's rights for investors.
Takes note of the GEF annual report andnotes the SCF's recommendations regarding draft guidance to the GEF;
The FDA released a draft guidance on developing drugs to treat breast cancer in men.
On November 23, 2016, the Food and Drug Administration(FDA)published a revised draft guidance for Submission of Quality Metrics Data.
FDA releases draft guidance on expansion of abbreviated 510(k) Program.
We do not intend to re-issue these draft guidance documents or the CPG.
This draft guidance will be applied on a 6-month trial basis by PIC/S Participating Authorities.
On July 28, 2015, the FDA published a draft guidance, entitled“Request for Quality Metrics.”.
This draft guidance will be applied on a 6-month trial basis by PIC/S Participating Authorities.
As a result, the FATF plans to release draft guidance on digital identity for public comment.
The draft guidance is intended to help the food industry and others comply with prior notice requirements.
In November 2016, the FDA issued a Draft Guidance on the Submission of Quality Metrics Data.
In its draft guidance, FDA said prior authorization is necessary before introducing any food from such livestock into the food supply.
On November 23, 2016, the FDA issued a draft guidance entitled, Submission of Quality Metrics Data.
FDA Draft Guidance(January 2017) on Biosimilars provides greater clarity on regulatory requirements and the type of data sponsors will need to provide to demonstrate interchangeability.
Impact to the bioanalytical community of the FDA issuance of the draft guidance on biomarker qualification(evidentiary framework).
The US FDA has issued draft guidance to the pharmaceutical industry outlining how risk information should be presented when advertising prescription drugs and medical devices.
The US Food and Drug Administration(FDA) recently published a draft guidance for how and when to include pregnant women in drug trials.
The FDA issued the draft guidance, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products.
As a result of the increased use of analytical instruments in the clinical field, the U.S. FDA(Food and Drug Administration)announced draft guidance in June 2011, requiring a clearer distinction between research equipment and IVD(in vitro diagnostic devices).
Last year it released a draft guidance, which is not yet legally binding, saying this process alters the cells too much and therefore should undergo FDA approval just like drugs.
Invites parties to submit annually to the Secretariat their views and recommendations on the elements to be taken into account in developing guidance to the GEF, andrequests the SCF to take into consideration these submissions when providing draft guidance to the GEF for consideration by the COP; and.
Many welcomed the SCF's report and draft guidance, noting they provided a good basis and reflected progress made.
On Dec. 23, 2015, FDA released draft guidance on the Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base.
Accordingly, FDA is withdrawing those draft guidances and CPG 7153.17 as well as the guidance on electronic copies of electronic records.
FDA received valuable public comment on the draft guidances and plans to use that information to inform the agency's future decisionmaking with respect to part 11.
FDA received valuable public comments on these draft guidances and plans to use that information to inform the Agency's future decision-making with respect to Part 11.
On December 23, 2015, the FDA published a draft guidance for industry"Advancement of Emerging Technology Applications to Modernize the Pharmaceutical Manufacturing Base".
The FDA has recently issued a draft guidance on“Use of electronic records and electronic signatures in clinical investigations under 21 CFR Part 11- Questions and Answers”.
As a response to that growth in 2017, the FDA issued a draft guidance, Use of Electronic Records and Electronic Signatures in Clinical Investigations under 21 CFR Part 11- Questions and Answers.